doi: 10.1161/CIRCULATIONAHA.104.498378
(Circulation. 2005;111:2783-2791.)
© 2005 American Heart Association, Inc.
Valvular Heart Disease |
From Stem Cells to Viable Autologous Semilunar Heart Valve
From the Department of Cardiovascular Surgery (F.W.H.S., T.E.P., Y.M., G.A.G., J.E.M.), Vascular Biology Program, Department of Surgery (Y.Y.), Department of Cardiology (M.C.S.), and Department of Surgery (D.L.M.), Children’s Hospital, Boston, Mass; Department of Pathology, Brigham and Women’s Hospital, Boston, Mass (E.B., F.J.S.); Harvard Medical School, Boston, Mass (F.W.H.S., T.E.P., Y.Y., M.C.S., E.B., Y.M., G.A.G., D.L.M., F.J.S., J.E.M.); and University of Pittsburgh, Department of Bioengineering, Pittsburgh, Penn (G.C.E., M.S.S.).
Correspondence to Fraser W.H. Sutherland, MA, MB, BChir, FRCS (Eng), FRCS (C-Th), Department of Cardiothoracic Surgery, Level 9, Western Infirmary, Dumbarton Rd, Glasgow, UK G11 6NT. E-mail fraser.sutherland{at}northglasgow.scot.nhs.uk
Received August 9, 2004; revision received December 30, 2004; accepted February 4, 2005.
Background— An estimated 275 000 patients undergo heart valve replacement each year. However, existing solutions for valve replacement are complicated by the morbidity associated with lifelong anticoagulation of mechanical valves and the limited durability of bioprostheses. Recent advances in tissue engineering and our understanding of stem cell biology may provide a lifelong solution to these problems.
Methods and Results— Mesenchymal stem cells were isolated from ovine bone marrow and characterized by their morphology and antigen expression through immunocytochemistry, flow cytometry, and capacity to differentiate into multiple cell lineages. A biodegradable scaffold was developed and characterized by its tensile strength and stiffness as a function of time in cell-conditioned medium. Autologous semilunar heart valves were then created in vitro using mesenchymal stem cells and the biodegradable scaffold and were implanted into the pulmonary position of sheep on cardiopulmonary bypass. The valves were evaluated by echocardiography at implantation and after 4 months in vivo. Valves were explanted at 4 and 8 months and examined by histology and immunohistochemistry. Valves displayed a maximum instantaneous gradient of 17.2±1.33 mm Hg, a mean gradient of 9.7±1.3 mm Hg, an effective orifice area of 1.35±0.17 cm2, and trivial or mild regurgitation at implantation. Gradients changed little over 4 months of follow-up. Histology showed disposition of extracellular matrix and distribution of cell phenotypes in the engineered valves reminiscent of that in native pulmonary valves.
Conclusions— Stem-cell tissue-engineered heart valves can be created from mesenchymal stem cells in combination with a biodegradable scaffold and function satisfactorily in vivo for periods of >4 months. Furthermore, such valves undergo extensive remodeling in vivo to resemble native heart valves.
Key Words: stem cells • tissue engineering • valves
Related Article:
Circulation 2005 111: 2715-2716.
This article has been cited by other articles:
 |
|
 |
|
  B. A. Mettler, V. L. Sales, C. L. Stucken, V. Anttila, K. Mendelson, J. Bischoff, and J. E. Mayer Jr Stem cell-derived, tissue-engineered pulmonary artery augmentation patches in vivo. Ann. Thorac. Surg., July 1, 2008; 86(1): 132 - 141. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. E. Mayer Tissue Engineering for Cardiac Valve Surgery Card. Surg. Adult, January 1, 2008; 3(2008): 1649 - 1656. [Full Text]
|
|
|
|
 |
|
 S. H. Goldbarg, S. Elmariah, M. A. Miller, and V. Fuster Insights Into Degenerative Aortic Valve Disease J. Am. Coll. Cardiol., September 25, 2007; 50(13): 1205 - 1213. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. L. Sales, G. C. Engelmayr Jr, J. A. Johnson Jr, J. Gao, Y. Wang, M. S. Sacks, and J. E. Mayer Jr Protein Precoating of Elastomeric Tissue-Engineering Scaffolds Increased Cellularity, Enhanced Extracellular Matrix Protein Production, and Differentially Regulated the Phenotypes of Circulating Endothelial Progenitor Cells Circulation, September 11, 2007; 116(11_suppl): I-55 - I-63. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Schmidt, J. Achermann, B. Odermatt, C. Breymann, A. Mol, M. Genoni, G. Zund, and S. P. Hoerstrup Prenatally Fabricated Autologous Human Living Heart Valves Based on Amniotic Fluid Derived Progenitor Cells as Single Cell Source Circulation, September 11, 2007; 116(11_suppl): I-64 - I-70. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Vincentelli, F. Wautot, F. Juthier, O. Fouquet, D. Corseaux, S. Marechaux, T. Le Tourneau, O. Fabre, S. Susen, E. Van Belle, et al. In vivo autologous recellularization of a tissue-engineered heart valve: Are bone marrow mesenchymal stem cells the best candidates? J. Thorac. Cardiovasc. Surg., August 1, 2007; 134(2): 424 - 432. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-H. Sievers In vivo tissue engineering an autologous semilunar biovalve: Can we get what we want? J. Thorac. Cardiovasc. Surg., July 1, 2007; 134(1): 20 - 22. [Full Text] [PDF]
|
|
|
|
|
|
K. Hayashida, K. Kanda, H. Yaku, J. Ando, and Y. Nakayama Development of an in vivo tissue-engineered, autologous heart valve (the biovalve): Preparation of a prototype model J. Thorac. Cardiovasc. Surg., July 1, 2007; 134(1): 152 - 159. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. W. Stephens, D. E. Price, A. Ionescu, H. Linkova, E. Ruzicka, M. Penicka, R. E. Kast, E. L. Altschuler, J. L. Ziegler, G. Y. Bukhman, et al. Dopamine Agonists and Valvular Heart Disease N. Engl. J. Med., April 19, 2007; 356(16): 1676 - 1680. [Full Text] [PDF]
|
|
|
|
|
|
D. Schmidt, L. M. Asmis, B. Odermatt, J. Kelm, C. Breymann, M. Gossi, M. Genoni, G. Zund, and S. P. Hoerstrup Engineered living blood vessels: functional endothelia generated from human umbilical cord-derived progenitors. Ann. Thorac. Surg., October 1, 2006; 82(4): 1465 - 1471. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Schmidt, A. Mol, C. Breymann, J. Achermann, B. Odermatt, M. Gossi, S. Neuenschwander, R. Pretre, M. Genoni, G. Zund, et al. Living Autologous Heart Valves Engineered From Human Prenatally Harvested Progenitors Circulation, July 4, 2006; 114(1_suppl): I-125 - I-131. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Cebotari, A. Lichtenberg, I. Tudorache, A. Hilfiker, H. Mertsching, R. Leyh, T. Breymann, K. Kallenbach, L. Maniuc, A. Batrinac, et al. Clinical Application of Tissue Engineered Human Heart Valves Using Autologous Progenitor Cells Circulation, July 4, 2006; 114(1_suppl): I-132 - I-137. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Mol, M. C.M. Rutten, N. J.B. Driessen, C. V.C. Bouten, G. Zund, F. P.T. Baaijens, and S. P. Hoerstrup Autologous Human Tissue-Engineered Heart Valves: Prospects for Systemic Application Circulation, July 4, 2006; 114(1_suppl): I-152 - I-158. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. P. Hoerstrup, I. Cummings MRCS, M. Lachat, F. J. Schoen, R. Jenni, S. Leschka, S. Neuenschwander, D. Schmidt, A. Mol, C. Gunter, et al. Functional Growth in Tissue-Engineered Living, Vascular Grafts: Follow-Up at 100 Weeks in a Large Animal Model Circulation, July 4, 2006; 114(1_suppl): I-159 - I-166. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. L. Sales, G. C. Engelmayr Jr, B. A. Mettler, J. A. Johnson Jr, M. S. Sacks, and J. E. Mayer Jr Transforming Growth Factor-{beta}1 Modulates Extracellular Matrix Production, Proliferation, and Apoptosis of Endothelial Progenitor Cells in Tissue-Engineering Scaffolds Circulation, July 4, 2006; 114(1_suppl): I-193 - I-199. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. F. Badylak Regenerative Medicine Approach to Heart Valve Replacement Circulation, May 31, 2005; 111(21): 2715 - 2716. [Full Text] [PDF]
|
|